{"name":"Nanjing Chia-tai Tianqing Pharmaceutical","slug":"nanjing-chia-tai-tianqing-pharmaceutical","ticker":"","exchange":"","domain":"nanjingchiataitianqing.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"NTQ1062+Fulvestrant","genericName":"NTQ1062+Fulvestrant","slug":"ntq1062-fulvestrant","indication":"Hormone receptor-positive, HER2-negative metastatic breast cancer","status":"phase_3"},{"name":"Placebo + fulvestrant","genericName":"Placebo + fulvestrant","slug":"placebo-fulvestrant","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Obeticholic Acid Tablets（OCA）","genericName":"Obeticholic Acid Tablets（OCA）","slug":"obeticholic-acid-tablets-oca","indication":"Primary biliary cholangitis (PBC)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"succinylated gelatin injection","genericName":"succinylated gelatin injection","slug":"succinylated-gelatin-injection","indication":"Hypovolemia and shock requiring fluid resuscitation","status":"marketed"}]}],"pipeline":[{"name":"Obeticholic Acid Tablets（OCA）","genericName":"Obeticholic Acid Tablets（OCA）","slug":"obeticholic-acid-tablets-oca","phase":"phase_3","mechanism":"Obeticholic acid is a farnesoid X receptor (FXR) agonist that reduces bile acid synthesis and improves liver function by modulating nuclear receptor signaling.","indications":["Primary biliary cholangitis (PBC)","Primary sclerosing cholangitis (PSC)","Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)"],"catalyst":""},{"name":"NTQ1062+Fulvestrant","genericName":"NTQ1062+Fulvestrant","slug":"ntq1062-fulvestrant","phase":"phase_3","mechanism":"NTQ1062 is a selective estrogen receptor degrader (SERD) combined with fulvestrant, an estrogen receptor antagonist, to block estrogen signaling in hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative metastatic breast cancer"],"catalyst":""},{"name":"Placebo + fulvestrant","genericName":"Placebo + fulvestrant","slug":"placebo-fulvestrant","phase":"phase_3","mechanism":"Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, while placebo serves as a control arm in this combination study.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"succinylated gelatin injection","genericName":"succinylated gelatin injection","slug":"succinylated-gelatin-injection","phase":"marketed","mechanism":"Succinylated gelatin acts as a plasma volume expander by increasing colloid osmotic pressure to restore intravascular fluid volume.","indications":["Hypovolemia and shock requiring fluid resuscitation","Perioperative volume replacement during surgery"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOUVpfcDNiUGZnelozQmZqTjd6aGxPZXBKa2s0cHVQa055WUthRGJab2pzTVZqVjNhLUxhQUJocmZLQVF6aVNtNXJJR1pXeWRhTEp1NkhqYVpXenBMMkViN3pYd3E5OEJ0SEpXM3ktaUFYZE9Wd3YyX0llSGhKNmhCX3phZ2NmUWpBYVNYZjQ5OGhQLWh5Y0RsQnFJUnM0enZFWTlTYkhUS0NLendHclJvRERn?oc=5","date":"2026-03-04","type":"deal","source":"fiercepharma.com","summary":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset - fiercepharma.com","headline":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOd1p5eUVSN2hiWWtQVTRtdUpxaWExSXZ6OHJfd3U4eFVrWFdxeGtLMlNUa2diSFZBeFZ2bTJQb1U4Z3pVNDQzRldaMUhtSVQ1bHZMY0FabXZaOUhBNFV3bDI1NEdnWC0zaXhuWmRmRXFVMzJIc29hMmlFeU5Pd0QxYzRUWTkzbVE?oc=5","date":"2025-09-19","type":"pipeline","source":"BioWorld News","summary":"Genfleet raises $234M with Hong Kong IPO - BioWorld News","headline":"Genfleet raises $234M with Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPR2dnWnlRRGVKdFVOZlExUGcyU2xONTZnQ2lPVGU2eXM3OXdzX3p5TFZQM2FWaTJEaEczSVlaTm1DZVhTU0ZIRS1jd3AxeWV1YWU5TXRMWmE3RkIyU21xSERTdFF6V3paeFRDVzNYY1JBQkJ2cWlJME1sc25VVktCWmlteEE1Qm0xTVE?oc=5","date":"2025-06-04","type":"regulatory","source":"Yahoo Finance","summary":"Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) - Yahoo Finance","headline":"Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BC","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOM0JDRFg5em1wWkhpUkZWa3RGanRlaFFNX2FYbjJoNmxjcF8talg4bkhmOFkyVk9xNHNhS2pIQ1R3c3ZkZHE1elRxemdFRE52dlg1QjNOV29HX0dKTWQ2R2JweU1nZXJFVWtveFZMS1R5ZGd0TEwwamlYMTR0eEk3b1hOVWItZVVrbHN1cHBfVmhaLVlnZ3pNb1c2T0JKT2tjNWVsREZzQQ?oc=5","date":"2024-09-26","type":"pipeline","source":"Citeline News & Insights","summary":"BIOSECURE Act: Potential Supply Chain Hits And Pharma’s Path Ahead - Citeline News & Insights","headline":"BIOSECURE Act: Potential Supply Chain Hits And Pharma’s Path Ahead - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQR0FlZVdKcWI5ODlyTnhNUnFaOWlNeFVtcWpQN2RjNlkwX3dXVnl6SWdrUWhycXBNd0UxNVBLMTk4aXotVmVlenBDSlItUE9Fd0dXa01pdS1sZm1ONDNjaWsxeWZiQzRibmh3QjR6ZC1VaUdoOWVxTDFURl9tdUJ6MlBlRVFURHp2UnBoM1ZSckw3LV8wcjF3ZFRwdHJHaGplOTViamkxamlYQQ?oc=5","date":"2024-09-23","type":"pipeline","source":"Citeline News & Insights","summary":"BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps? - Citeline News & Insights","headline":"BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps? - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOcVZRRENYWF9Ld09GXzVFS1g5a0VfUHREMzhTSXp0SGVPZ3BIN2JiVjdpclFpZjdGQWh4eHZrekFzWW9FcnpwM3I0Q2VnTzUzTUNBc0hjenN1dVdOeTFtbzl3dEVYVnRqcHpTT2FyM3F3Zkg3bFNPNGVoS0tCUF9lMWY2RzR1eUhGcklRTjBGcjhBVHpfZnFhZ2NmYzRYVDhMM1U4MA?oc=5","date":"2024-03-18","type":"deal","source":"BioWorld News","summary":"Biotheus, Hansoh ink potential ¥5B deal for new bispecific ADCs - BioWorld News","headline":"Biotheus, Hansoh ink potential ¥5B deal for new bispecific ADCs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-05-31","type":"trial","source":"GlobeNewswire","summary":"B-Cell Lymphoma Clinical Trial Pipeline Insights: - GlobeNewswire","headline":"B-Cell Lymphoma Clinical Trial Pipeline Insights:","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}